Regime mapping and the role of the intermediate region in wall-coated microreactors

Operation of a wall-coated microreactor can occur in several mass transfer-reaction regimes. We define these regimes analytically in several planes of a multi-parametric map, taking into account the different degrees of concentration profile development, as well as the influence of non-unity orders of reaction and reactant inhibition in the kinetic law. It was found that the regions where conversion can be calculated from simplified mass transfer models are not discriminated by common results for entrance-length. We also illustrate the trade-offs that exist across this operating map concerning the catalyst design (costs associated with loading and volume) and overall system performance (evaluated in terms of reactant conversion, flow efficiency and microreactor effectiveness). It is shown that under certain conditions, the existence of moderate mass transfer resistance can be advantageous (even if internal limitations cannot be avoided), clarifying the role of the intermediate transport-reaction region

Lack of association between RNASEL Arg462Gln variant and the risk of breast cancer

Background: The RNASEL G1385A variant was recently found to be implicated in the development of prostate cancer. Considering the function of RNase L and the pleiotropic effects of mutations associated with cancer, we sought to investigate whether the RNASEL G1385A variant is a risk factor for breast cancer. Patients and Methods: A total of 453 breast cancer patients and 382 age- and sex-matched controls from Greece and Turkey were analyzed. Genotyping for the RNASEL G1385A variant was performed using an Amplification Refractory Mutation System (ARMS). Results: Statistical evaluation of the RNASEL G1385A genotype distribution among breast cancer patients and controls revealed no significant association between the presence of the risk genotype and the occurrence of breast cancer. Conclusion: Although an increasing number of studies report an association between the RNASEL G1385A variant and prostate cancer risk, this variant does not appear to be implicated in the development of breast cancer